NCT04428775View on ClinicalTrials.gov

A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

October 1, 2021

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

ALZT-OP1a (cromolyn)

"1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory"

Trial Locations (6)

10021

Hospital for Special Surgery, New York

10032

Columbia University Medical Center, New York

27157

Wake Forest School of Medicine, Winston-Salem

32224

Mayo Clinic, Jacksonville

92037

UCSD Altman Clinical and Translational Research Institute, La Jolla

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

AZTherapies, Inc.
All Listed Sponsors
lead

AZTherapies, Inc.

INDUSTRY